PLoS ONE (Jan 2020)

Gender difference in ASAS HI among patients with ankylosing spondylitis.

  • Hsin-Hua Chen,
  • Yi-Ming Chen,
  • Kuo-Lung Lai,
  • Tsu-Yi Hsieh,
  • Wei-Ting Hung,
  • Ching-Tsai Lin,
  • Chih-Wei Tseng,
  • Kuo-Tung Tang,
  • Yin-Yi Chou,
  • Yi-Da Wu,
  • Chin-Yin Huang,
  • Chia-Wei Hsieh,
  • Wen-Nan Huang,
  • Yi-Hsing Chen

DOI
https://doi.org/10.1371/journal.pone.0235678
Journal volume & issue
Vol. 15, no. 7
p. e0235678

Abstract

Read online

ObjectiveTo assess the associations of the Assessment of Spondyloarthritis International Society Health Index (ASAS HI) with gender and other factors in patients with ankylosing spondylitis (AS).MethodsFrom November 2017 to October 2018, we measured the Ankylosing Spondylitis Disease Activity Score (ASDAS), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) and the ASAS HI score for AS patients at the Taichung Veterans General Hospital. After adjusting for disease activity (ASDAS-erythrocyte sedimentation rate [ESR], ASDAS- C-reactive protein [CRP], BASDAI+ESR or BASDAI+CRP), mSASSS and other potential confounders including medications, comorbidities, and laboratory data, any associations between gender and the sum score of ASDAS HI were assessed using multiple linear regression analysis, as well as any associations between gender and an ASAS HI score >5 using multivariable logistic regression analysis.ResultsA total of 307 AS patients (62 [20.2%] females, mean age 46.4 years [S.D. 13.3], mean symptom duration 20.6 years [S.D. 12.1]) were included. Multiple linear regression analysis showed that the male gender was significantly associated with a lower ASAS HI (B = -1. 91, 95% confidence interval [CI], -2.82--1.00, p 5 than females (odds ratio = 0.15, 95% CI, 0.07-0.36, p ConclusionThis single-center, cross-sectional study revealed that a higher ASAS HI score was significantly associated with female gender and higher disease activity measures.